Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses Meeting Abstract
| Authors: | Lei, M.; Janjigian, Y. Y.; Ajani, J. A.; Moehler, M.; Wang, X.; Shen, L.; Garrido, M.; Gallardo, C.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; Liu, T.; Tehfe, M.; Elimova, E.; Li, M.; Poulart, V.; Wang, Y.; Doshi, P.; Shitara, K. |
| Abstract Title: | Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses |
| Meeting Title: | 113th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 82 |
| Issue: | 12 Suppl. |
| Meeting Dates: | 2022 Apr 8-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-06-15 |
| Language: | English |
| ACCESSION: | WOS:000892509500148 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.AM2022-CT023 |
| Notes: | Meeting Abstract: CT023 -- Source: Wos |
